Psilocybin for Treatment-Resistant Depression: The Largest European Trial Shows Mixed Results
- Phase 2b RCT (EPIsoDE): 144 patients with treatment-resistant major depression. Psilocybin 25mg + adjunct short-term psychotherapy vs control
- Missed the primary endpoint — no statistically significant difference in the proportion achieving ≥50% symptom improvement
- Clinically meaningful benefit observed on secondary outcome measures (depression severity, functional improvement)
- Authors note "divergence between primary and secondary outcomes renders the findings inconclusive." Blinding concerns raised in companion analysis
The largest European psilocybin trial for depression delivers a result that neither enthusiasts nor sceptics will find comfortable. It missed its primary endpoint. It showed benefit on secondary measures. For evidence-based practitioners watching the psychedelic therapy wave, this is exactly the kind of data that demands nuanced interpretation — not headlines.
The EPIsoDE design
The trial randomised 144 patients with treatment-resistant major depression — a population that has failed at least two adequate antidepressant trials. The intervention was psilocybin 25mg combined with structured short-term psychotherapy, compared against a control condition. This was Phase 2b — designed to inform dosing and efficacy for a potential Phase 3 programme.
The primary endpoint was the proportion of patients achieving ≥50% reduction in depressive symptoms. Psilocybin did not significantly outperform the control on this measure. That is a failed primary endpoint — and in drug development, primary endpoints matter because they are pre-registered and protect against post-hoc cherry-picking.
However, secondary outcomes — including continuous depression severity scores and functional measures — showed statistically significant benefit. The authors acknowledge this divergence honestly: the findings are "inconclusive."
Why the nuance matters
A companion paper raised concerns about blinding integrity — whether participants could tell if they received psilocybin or placebo. This is the fundamental methodological challenge of psychedelic research: the subjective experience is difficult to mask, which inflates placebo-group expectations and potentially biases self-report outcomes.
For clinicians, the takeaway is calibration. Psilocybin may have antidepressant properties. But the evidence is not yet strong enough to recommend it as a treatment for treatment-resistant depression. The EPIsoDE trial is a signal, not a verdict.
The largest European psilocybin trial for depression missed its primary endpoint but showed secondary benefit — a signal that demands careful interpretation, not enthusiasm or dismissal.
Blinding integrity concerns. Treatment-resistant population may respond differently than broader MDD. Psilocybin combined with psychotherapy — cannot isolate which component drives effect. Single 25mg dose; other dosing strategies untested.